Visfatin serum level and expression in subcutaneous and visceral adipose tissue in prepubertal boys

Novak, Sanja; Divković, Dalibor; Drenjančević, Ines; Ćosić, Anita; Selthofer-Relatić, Kristina

doi:10.1111/ijpo.12080

Cited by 6 publications

(5 citation statements)

References 31 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also showed, for the first time, that visfatin increased significantly with obesity not only in adolescents but also in prepubertal children with obesity aged below 7 years. There is also a previous study showing an increase in visfatin mRNA expression in the subcutaneous adipose tissue of children aged 7-10 years, but this did not correlate with an increase in serum visfatin [45]. Our results could possibly be indicative in this young age-group with obesity, as in the AO, of other additional mechanisms that contribute to the metabolic state of obesity currently described as "low-grade inflammation" [46].…”

Section: Discussion/conclusionsupporting

confidence: 42%

Adiponectin Signaling and Impaired GTPase Rab5 Expression in Adipocytes of Adolescents with Obesity

et al. 2020

View full text Add to dashboard Cite

Introduction: Abnormalities in adipose tissue AdipoR1; adaptor protein, phosphotyrosine interaction, PH domain, and leucine zipper containing 1 (APPL1); GTPase Rab5; adiponectin; leptin; and visfatin in adults with obesity have been associated with metabolic disturbances. Objective: The objective of this study was to examine whether pediatric obesity disrupts elements of the adiponectin signaling pathway and GTPase Rab5 in adipose tissue. Methods: Primary adipocyte cultures of subcutaneous abdominal tissue were obtained from 96 lean and 66 children and adolescents with obesity (AO). AdipoR1, APPL1, and GTPase Rab5 mRNA levels were measured by RT-PCR and their protein content by Western immunoblotting. Serum total and high-molecular-weight adiponectin, leptin, leptin soluble receptor (sOB-R), and visfatin were measured by ELISA. Results: The mRNA expression and protein content of AdipoR1 and APPL1 did not differ significantly with obesity, age, or puberty. However, GTPase Rab5 protein was increased in the adipocytes of younger prepubertal children with obesity but decreased in AO. Leptin was increased in AO compared to lean adolescents (AL) and in older prepubertal lean (OPL) children and AL compared to younger prepubertal lean and obese children. sOB-R was higher in OPL children and in the AL and AO. Serum visfatin was increased in the younger prepubertal children and AO. Conclusions: In contrast to adults, obesity did not change the expression of AdipoR1 and APPL1 in cultured adipocytes from biopsies of subcutaneous abdominal adipose tissue of children and adolescents. Similar to adipose tissue studies in adults with obesity and metabolic dysfunction, the AO in our study showed reduced adipocyte GTPase Rab5 expression.

show abstract

Section: Discussion/conclusionsupporting

confidence: 42%

Adiponectin Signaling and Impaired GTPase Rab5 Expression in Adipocytes of Adolescents with Obesity

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Visfatin is produced by visceral adipose tissue, and it is secreted in response to inflammatory stimuli. 37 Visfatin can upregulate the production of some major cytokines, such as interleukin 1 and tumor necrosis factor α. 36 Dahl et al found that visfatin, as an inflammatory mediator highly expressed in lipid-loaded macrophages of unstable atherosclerotic lesions, played a potential important role in plaque destabilization by regulating matrix metalloproteinase 9 activity.…”

Section: Discussionmentioning

confidence: 99%

Increased Peripheral Blood Visfatin Concentrations May Be a Risk Marker of Coronary Artery Disease: A Meta-Analysis of Observational Studies

Huang

et al. 2018

Angiology

View full text Add to dashboard Cite

A comprehensive quantitative evaluation of the relationship between peripheral blood visfatin concentrations and coronary artery disease (CAD) is lacking. This study is the first attempt to quantify this relationship via a meta-analysis of published observational studies in terms of weighted mean difference (WMD). Literature retrieval, article selection, and data extraction were conducted. Heterogeneity was inspected using both subgroup and meta-regression analyses. In total, 15 articles involving 1053 CAD cases and 714 controls were included. Overall, peripheral blood visfatin concentrations were significantly higher in CAD cases than in controls (WMD: 4.72 ng/mL; 95% confidence interval [CI]: 2.97-6.47; P < .001), with significant heterogeneity and publication bias. Six studies were theoretically missing based on filled funnel plot, and considering the impact of these missing studies still detected a significant overall mean difference in visfatin (WMD: 2.82 ng/mL; 95% CI: 2.22-3.58; P < .001; number of studies: 21). Subgroup and meta-regression analyses indicated age, body mass index, race, diabetes, systolic blood pressure, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol were identified as possible causes of heterogeneity. In conclusion, our findings suggest that increased peripheral blood visfatin concentrations may be a risk marker of CAD.

show abstract

“…It is noteworthy that OA and OP have been associated with several metabolic alterations, most of them part of metabolic syndrome [4,5,6,7]. Interestingly, visfatin was also associated to several OA and OP shared metabolic alterations, namely cardiovascular hypertension and obesity [9,12,13,14,15,73,74], insulin resistance [75,76], and type 1 (T1DM) [16] and 2 diabetes mellitus (T2DM) [17,18,77] (Figure 2).…”

Section: Visfatin In Oa and Op Shared Risk Factorsmentioning

confidence: 99%

“…Specifically, obese patients have elevated secretion levels of visfatin [9,12,13,14,15,73,74]. Moreover, leukocytes’ visfatin levels are higher in those patients compared to lean ones [78,79], which correlates with an increased visfatin secretion by adipose tissue-derived macrophages [80].…”

Section: Visfatin In Oa and Op Shared Risk Factorsmentioning

confidence: 99%

“…In fact, the tight relationship of visfatin synovial fluid levels with synovium inflammatory responses, cartilage degradation, and osteophyte formation may provide an accurate description of the catabolic and inflammatory processes taking place at incipient OA joints [100,101,103,104]. Nevertheless, it is noteworthy that certain OA comorbidities modulate visfatin’s circulating level, which may represent the biggest pitfall to overcome for its use as an OA-biomarker [9,12,13,14,15,16,17,18,73,74,75,76,77].…”

Section: Visfatin As a Potential Biomarker And Therapeutic Targetmentioning

confidence: 99%

See 1 more Smart Citation

Visfatin Connection: Present and Future in Osteoarthritis and Osteoporosis

Franco-Trepat

Guillán-Fresco

Alonso-Pérez

et al. 2019

JCM

View full text Add to dashboard Cite

Musculoskeletal pathologies (MSPs) such as osteoarthritis (OA) and osteoporosis (OP), are a set of disorders that cause severe pain, motion difficulties, and even permanent disability. In developed countries, the current incidence of MSPs reaches about one in four adults and keeps escalating as a consequence of aging and sedentarism. Interestingly, OA and OP have been closely related to similar risk factors, including aging, metabolic alterations, and inflammation. Visfatin, an adipokine with an inflammatory and catabolic profile, has been associated with several OA and OP metabolic risk factors, such as obesity, insulin resistance, and type II diabetes. Furthermore, visfatin has been associated with the innate immune receptor toll-like receptor 4 (TLR4), which plays a key role in cartilage and bone inflammatory and catabolic responses. Moreover, visfatin has been related to several OA and OP pathologic features. The aim of this work is to bring together basic and clinical data regarding the common role of visfatin in these pathologies and their major shared risk factors. Finally, we discuss the pitfalls of visfatin as a potential biomarker and therapeutic target in both pathologies.

show abstract

Visfatin serum level and expression in subcutaneous and visceral adipose tissue in prepubertal boys

Cited by 6 publications

References 31 publications

Adiponectin Signaling and Impaired GTPase Rab5 Expression in Adipocytes of Adolescents with Obesity

Adiponectin Signaling and Impaired GTPase Rab5 Expression in Adipocytes of Adolescents with Obesity

Increased Peripheral Blood Visfatin Concentrations May Be a Risk Marker of Coronary Artery Disease: A Meta-Analysis of Observational Studies

Visfatin Connection: Present and Future in Osteoarthritis and Osteoporosis

Contact Info

Product

Resources

About